A. Primary activities
i) Manufacturing using patented technology such as techno sphere formulation technology, which makes pulmonary delivery of drugs typically delivered through injections possible. Other technologies are also utilized in the production of the AFREZZA powder, such as the dip dots machine, which the company uses to produce uniformed little chunks of the powder.
ii) Research and Clinical Trials
iii) Reception of FDA approval for the distribution of the various products
iv) Large scale production on the product AFREZZA
v) Licensing of a partner pharmaceutical company
vi) Marketing and Sales
vii) Further research and development, as well as improvements on the pilot product, as well as the introduction of other products.
viii) Invention of various technologies that make the production of unique products possible
B. Support activities
i) Raising of capital through stock sales as well as through long-term loans and making alternative investments
ii) Searching for and negotiating with the ideal pharmaceutical company that has a global reach.
INTERNAL ENVIRONMENT
- Corporate Structure
• The company has a multi-unit organizational structure which is a type of structure that groups the company’s employees based on both function and product/division specialization. MannKind offices are divided into three based on geographical location of the offices. The company has offices in California, New Jersey and Connecticut. The headquarters of the company is based in Valencia, California and all the three divisions have different functions.
- Corporate Resources
• MannKind Corporation faces a number of challenges, top of the list being the reception of FDA approval for its main therapy AFREZZA. Failing to receive approval will essentially result in the corporation having to shut down. Actually, each time approval has been denied (twice), the company has had to shed approximately 40% of its staff. Further delays cannot be sustained, as currently, the corporation is operating on a monthly budget of about $10- $12 million
• In case FDA approval is achieved, the product is projected to generate about $2000 in net profit if it partners with large drug companies to market their products. Combined with the advantages the product has over drugs aimed at providing similar relief, such as Metamorphin, the chances of the drug performing quite well in the market are good. The facility as currently equipped is actually capable of handling the demands of about 2,000,000 patients, translating to revenues of about $4 billion
• The corporation’s future upon receiving FDA approval looks bright, more so due to the strong governance structure it has put in place, as well as the obvious fact that it has at its helm one of the most capable CEOs in the industry. As an individual, the CEO invented insulin pumps as well as the very first cardiac pacemaker.
• With the tapping of the 4-P marketing strategy, MannKind stands to benefit in terms of setting prices which are favorable for their customers. They also locate their outlets and distribute their products through outlets with advantage of place. This is not to mention the superior quality of their products in the market and the promotions undertaken to popularize and reach their target customers
